Unilever Didn't Reshape Its Portfolio. It Was Pushed.

On 15 January 2022, the news that Unilever wanted to buy GSK's consumer health business did not come from Unilever. It came from GSK, which calmly disclosed that it had received and rejected three separate unsolicited bids from Unilever, the largest valuing the unit at £50bn - £41.7bn in cash and £8.3bn in shares.⁵ A target announcing its own suitor is not how confident acquirers operate. It is how a target raises the floor and dares the bidder to walk. Within four weeks, the bidder walked.⁶

The official story of the years that followed is a tidy one: Unilever, under new leadership, boldly pruned a sprawling conglomerate down to a focused four-segment machine, shedding the awkward ice cream business to concentrate on beauty, personal care, home care, and food. It is a flattering narrative. It is also backwards.

Unilever's portfolio reshape was not a plan executed from strength. It was a retreat conducted under fire - the GSK humiliation exposing a hollow adjacency thesis, and the ice cream spin-off forced out of a division that had been losing share and disappointing investors for years. The thesis here is simple: when a company tells you it is focusing, check whether it chose to, or whether it was made to.

The GSK bid told on itself

Unilever framed the GSK approach as an adjacency play - health, beauty, and hygiene as natural neighbours to its existing shelf. On paper, plausible. In practice, the price gave the game away. The final rejected offer represented only about a 10% premium over the business's existing value, while sources close to Pfizer - the 32% partner in the GSK joint venture - signalled that nothing under £60bn, a roughly 25% premium, would be taken seriously.⁷ A bidder who truly believes in an adjacency pays for it. Unilever lobbed in a number designed to look bold while costing little, and was told to go home three times.

Then came the part that mattered more than the rejection. Unilever's own shareholders revolted - not at the price, but at the very idea of a transformational deal from a management team that had not yet fixed the business it already owned. The pushback was severe enough that the CEO publicly surrendered the strategy within a month and handed investors a consolation prize.⁶ When you have to announce a €3bn buyback to apologise for a strategy, the strategy was never really yours.

Ice cream wasn't pruned. It was a problem being managed.

Ice cream was never a peripheral rounding error in the Unilever empire. In FY2023 it generated €7.9bn in turnover - 13% of group revenue, the third-largest of five business groups - and it grew to €8.28bn, or 14%, by FY2024.⁴ You do not casually shed a division that size to sharpen focus. You shed it because it has become the part of the portfolio you can least defend.

And it had. Unilever's own words for the FY2023 ice cream performance were 'disappointing,' with volumes down 6.0% and share bleeding to private label.⁴ That is the real engine of the spin-off announced on 19 March 2024 - paired, tellingly, with a productivity programme targeting €800m in savings and up to 7,500 job cuts.¹ A genuine focus play frees capital for the things you love. This freed capital from the thing you could no longer fix, with the seasonality, the cold chain, and the cabinet network sitting awkwardly inside a fast-moving consumer goods business built for shelf-stable products.

Even the execution carried the marks of a forced move rather than a confident one. The separation was announced in March 2024 with the route still undecided - demerger preferred, but a sale and other options explicitly left on the table.¹ It was not until 13 February 2025 that Unilever confirmed both the demerger and the new name, The Magnum Ice Cream Company.² And the company did not even walk away clean: at completion it kept a roughly 19.9% stake, to be sold down over time to cover separation costs and preserve flexibility, handing the other 80.1% to shareholders at one TMICC share for every five Unilever shares.³ You hold onto a fifth of something you genuinely wanted gone only if the exit was about housekeeping, not conviction.

Isn't a focused company still the right outcome?

The fair objection is that motives are cheap and results are real: whatever pushed Unilever to act, it now runs a leaner business of four continuing groups - Beauty & Wellbeing, Personal Care, Home Care, and Foods - with ice cream reported as discontinued operations and a productivity programme running ahead of schedule.⁹ A forced retreat that lands in a better place is still a better place. That is true, and it is the strongest case the reshape has.

But the burden of proof has simply moved, not disappeared. Discontinued ice cream still generated €7,691m of turnover in 2025 - a real business now standing on its own, debuting at roughly a €7.9bn market cap with about 21% of the global ice cream market and the world's largest cabinet fleet at some 3 million units.⁹⁸ Unilever did not destroy that value; it gave it away. The question that decides whether this was strategy or retreat is whether the four remaining segments can now grow faster than the €8bn business they shed - because if they can't, focus was just a smaller stage for the same problem. A reshape only counts as vision if the part you kept outgrows the part you let go.

Unilever's two big moves of the decade are usually told as opposites - a failed acquisition and a successful spin-off. They are the same move seen twice: a company reacting to its own weakness, dressed up as a company exercising its judgment. The GSK bid was a hollow adjacency the market refused to fund. The ice cream demerger was a struggling division the market wanted out. Neither began with conviction; both ended with Unilever doing what its investors demanded. The leaner Unilever may yet prove the doubters wrong. But it will have to prove it - because focus you were forced into isn't a strategy. It's just the shape your hand was forced into, and now you have to make it pay.